Rheincell Therapeutics

Langenfeld, Germany Founded: 2017 • Age: 9 yrs Acquired By Catalent
iPS cells are developed for therapeutics to prevent immune rejection.
Request Access

About Rheincell Therapeutics

Rheincell Therapeutics is a company based in Langenfeld (Germany) founded in 2017 was acquired by Catalent in June 2021.. Rheincell Therapeutics operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.

  • Headquarter Langenfeld, Germany
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Rheincell Therapeutics Gmbh
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Catalent

    (Jun 24, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Rheincell Therapeutics

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Rheincell Therapeutics

Rheincell Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Catalent. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
CDMO offering drug and biologics development services
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Rheincell Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Rheincell Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Rheincell Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Rheincell Therapeutics

Rheincell Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of pharmaceuticals and vaccines for various therapeutic areas
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Yeast cells are genetically engineered to produce medicinal products.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
domain founded_year HQ Location
CRISPR-engineered cell and gene therapies are developed for research applications.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Rheincell Therapeutics

Frequently Asked Questions about Rheincell Therapeutics

When was Rheincell Therapeutics founded?

Rheincell Therapeutics was founded in 2017.

Where is Rheincell Therapeutics located?

Rheincell Therapeutics is headquartered in Langenfeld, Germany. It is registered at Langenfeld, North Rhine-westphalia, Germany.

Who is the current CEO of Rheincell Therapeutics?

Jurgen Weisser is the current CEO of Rheincell Therapeutics.

What does Rheincell Therapeutics do?

Rheincell Therapeutics was founded in 2017 in Langenfeld, Germany, within the biotechnology sector. Focus is placed on induced pluripotent stem (iPS) cells as a platform for cell-based therapies. A master cell bank is maintained to serve as starting material for various therapeutic applications, aiming to reduce immune rejection in recipients. Operations center on creating scalable sources for iPSC-derived treatments.

Who are the top competitors of Rheincell Therapeutics?

Rheincell Therapeutics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

Who are Rheincell Therapeutics's investors?

Rheincell Therapeutics has 1 investor. Key investors include Catalent.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available